Lab, pathology, physical & occupational therapy, DME, home health, and home infusion live and die by the fee schedule — the rates most often overlooked at the negotiating table. Fulcrum Health Partners helps ancillary providers benchmark rates, win better terms, and open new locations with market intelligence and best-in-class payer transparency data.
Ancillary rates are set by government fee schedules — and quietly copied into commercial contracts.
Lab (PAMA/CLFS), therapy (MPFS), DME (DMEPOS), and home health (PDGM) all anchor to Medicare fee schedules. When those rates are frozen or cut, the reductions propagate straight into commercial agreements — often without anyone at the table advocating for the ancillary line.
Layer on stacked reductions, competitive-bidding gaps, behavioral adjustments, and structurally underfunded benefits like home infusion, and ancillary providers face rate pressure with the least negotiating support of any segment. Fulcrum changes that with fee-schedule benchmarking and payer transparency data.
Figures reflect current CMS/MedPAC methodology and industry sources, 2024–2026.
Transparency data reveals where market rates really sit — and how much headroom your contracts are leaving on the table.
Each ancillary segment has its own payment system, benchmark, and pressure points. We know all of them.
PAMA/CLFS dynamics, commercial rate strategy, and network positioning.
MPFS pressure, KX thresholds, MPPR, and PTA/OTA differentials.
DMEPOS fee schedule, competitive-bidding gaps, and rate adjustments.
PDGM 30-day periods, behavioral adjustments, and commercial strategy.
Benefit-design gaps, per-visit payment, and medical vs. pharmacy strategy.
Imaging, sleep, wound care, and specialty ancillary lines.
Home infusion carries some of the most complex reimbursement in the ancillary world — split across drug, per-visit, and medical-vs-pharmacy benefits. Select a profile to explore a sample view.
Illustrative sample dashboard. Fulcrum builds these from your billing data across medical and pharmacy benefit claims.
Therapy payment is squeezed from several directions at once. These are the fee-schedule facts every PT/OT leader is managing right now.
Sources: CMS Therapy Services & CY2026 Physician Fee Schedule; APTA. Figures current as of 2025–2026.
Not a service menu — the fee-schedule and network problems that decide ancillary margin, and the benchmarking, negotiation, and intelligence capabilities that resolve them.
The single most overlooked lever in ancillary reimbursement. We benchmark your rates against market and transparency data, then build the strategy to close the gap — code by code, payer by payer.
Ancillary providers are often an afterthought in network design. We secure access, defend against exclusion, and structure the carve-outs that protect specialized services.
Code- and claim-level modeling that turns your data and market transparency into a clear view of where you stand and what's achievable.
Open new locations with confidence. We bring payer transparency data and market intelligence to site selection, payer readiness, and de novo strategy.
We ensure contractual and fee-schedule entitlement becomes realized revenue — surfacing underpayments, modifier errors, and leakage.
For PE-backed and multi-site ancillary platforms, we bring institutional-grade reimbursement to diligence, integration, and expansion.
Each ancillary line faces its own fee-schedule threat. We translate every one into a rate and contract strategy.
CLFS rates frozen through 2026 with cuts of up to 15% scheduled to begin in 2027 — commercial rates follow.
Consecutive MPFS cuts stacked with MPPR and the PTA/OTA differential compress therapy margin from every side.
With no active bidding round and CPI-lagging updates, DMEPOS pricing sits in an uncertain, adjusted-rate limbo.
Compounding permanent and temporary behavioral adjustments continue to pull PDGM period payments down.
The Part B services benefit pays only when a clinician is in the home — leaving a documented reimbursement gap.
Ancillary services rarely have a dedicated advocate in payer negotiations — the gap Fulcrum is built to close.
Independent by design, fluent in every ancillary fee schedule, and armed with best-in-class payer transparency data.
No networks, no downstream fees — only your economics.
CLFS, MPFS, DMEPOS, PDGM, and home infusion — all of it.
Best-in-class market rate data to reveal true headroom.
Insight into payer behavior across every market.
Data-driven site selection and new-location strategy.
Access and carve-outs built for specialized services.
Quantified analysis behind every recommendation.
Dashboards and intelligence that clarify the path.
Anonymized outcomes from Fulcrum engagements with ancillary providers and platforms.
Fee-schedule benchmarking against transparency data exposed below-market rates — and built the case that lifted them.
Restructured medical-vs-pharmacy benefit strategy and per-visit capture to defend margin against benefit shifts.
Payer transparency data and market intelligence guided site selection and payer strategy for a confident expansion.
Executive briefings on the fee-schedule and network forces moving ancillary reimbursement — lab, therapy, DME, home health, and home infusion.
With best-in-class payer transparency data and deep fee-schedule expertise, Fulcrum Health Partners gives ancillary providers the advocate they've been missing — at the negotiating table and in every new market.